Research programme: anticancer antibodies - Affitech AS

Drug Profile

Research programme: anticancer antibodies - Affitech AS

Alternative Names: CBAS 1; CBAS 2; CBAS 4/5; CBAS 6

Latest Information Update: 18 Jan 2011

Price : $50

At a glance

  • Originator Affitech AS
  • Developer Affitech A/S
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
  • 20 Jan 2009 Affitech AS acquires Diabody technology from Pharmexa
  • 18 Apr 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top